Medication adherence with denosumab in patients with bone metastases from solid tumors treated in routine clinical settings: a retrospective study.

ABSTRACT:

Purpose

To describe (non)adherence with denosumab among patients with solid tumors and bone metastases.

Methods

This retrospective, observational study pooled data from two completed prospective, multicenter cohort studies (X-TREME; Study 240) in adult patients with bone metastases from primary breast, prostate, lung, kidney, or other solid cancer types and administered denosumab 120 mg in routine clinical practice in Germany and Central and Eastern Europe. The studies were conducted between May 2012 and May 2017; pooled analysis was completed in August 2021. Medication adherence was described according to a three-component consensus taxonomy: initiation (first-ever administration ≤ 90 days from bone metastasis diagnosis), implementation (actual vs prescribed dosing; optimal

SUBMITTER: Diel IJ 

PROVIDER: S-EPMC9446633 | biostudies-literature | 2022 Nov

REPOSITORIES: biostudies-literature